Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study

Qing Wang, Andrea De Luca, Colette Smith, Robert Zangerle, Helen Sambatakou, Fabrice Bonnet, Colette Smit, Philipp Schommers, Alicia Thornton, Juan Berenguer, Lars Peters, Vincenzo Spagnuolo, Adriana Ammassari, Andrea Antinori, Eugenia Quiros-Roldan, Cristina Mussini, Jose M. Miro, Deborah Konopnicki, Jan Fehr, Maria A CampbellMonique Termote, Heiner C. Bucher, Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

Research output: Contribution to journalArticle

3 Downloads (Pure)

Abstract

Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear.

Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIV-infected patients.

Design: Cohort study.

Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).

Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available.

Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring.

Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatment-naive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients.

Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group.

Conclusion: In HIV-infected patients receiving ART, chronic co-infection with HBV and HCV is associated with an increased risk for NHL.

Primary Funding Source: European Union Seventh Framework Programme.

Original languageEnglish
Pages (from-to)1-9
Number of pages9
JournalAnnals of Internal Medicine
DOIs
Publication statusE-pub ahead of print - Oct 18 2016

Fingerprint

Chronic Hepatitis B
Chronic Hepatitis C
Virus Diseases
Hepatitis B virus
Hepacivirus
Non-Hodgkin's Lymphoma
Cohort Studies
HIV
Therapeutics
RNA
Hepatitis C Antibodies
Incidence
European Union
Hepatitis B Surface Antigens
Coinfection
Proportional Hazards Models
Acquired Immunodeficiency Syndrome

Keywords

  • Journal Article

Cite this

Wang, Q., Luca, A. D., Smith, C., Zangerle, R., Sambatakou, H., Bonnet, F., ... Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord (2016). Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study. Annals of Internal Medicine, 1-9. https://doi.org/10.7326/M16-0240

Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients : A Cohort Study. / Wang, Qing; Luca, Andrea De; Smith, Colette; Zangerle, Robert; Sambatakou, Helen; Bonnet, Fabrice; Smit, Colette; Schommers, Philipp; Thornton, Alicia; Berenguer, Juan; Peters, Lars; Spagnuolo, Vincenzo; Ammassari, Adriana; Antinori, Andrea; Quiros-Roldan, Eugenia; Mussini, Cristina; Miro, Jose M.; Konopnicki, Deborah; Fehr, Jan; Campbell, Maria A; Termote, Monique; Bucher, Heiner C.; Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

In: Annals of Internal Medicine, 18.10.2016, p. 1-9.

Research output: Contribution to journalArticle

Wang, Q, Luca, AD, Smith, C, Zangerle, R, Sambatakou, H, Bonnet, F, Smit, C, Schommers, P, Thornton, A, Berenguer, J, Peters, L, Spagnuolo, V, Ammassari, A, Antinori, A, Quiros-Roldan, E, Mussini, C, Miro, JM, Konopnicki, D, Fehr, J, Campbell, MA, Termote, M, Bucher, HC & Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord 2016, 'Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study', Annals of Internal Medicine, pp. 1-9. https://doi.org/10.7326/M16-0240
Wang, Qing ; Luca, Andrea De ; Smith, Colette ; Zangerle, Robert ; Sambatakou, Helen ; Bonnet, Fabrice ; Smit, Colette ; Schommers, Philipp ; Thornton, Alicia ; Berenguer, Juan ; Peters, Lars ; Spagnuolo, Vincenzo ; Ammassari, Adriana ; Antinori, Andrea ; Quiros-Roldan, Eugenia ; Mussini, Cristina ; Miro, Jose M. ; Konopnicki, Deborah ; Fehr, Jan ; Campbell, Maria A ; Termote, Monique ; Bucher, Heiner C. ; Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord. / Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients : A Cohort Study. In: Annals of Internal Medicine. 2016 ; pp. 1-9.
@article{8ca8d6c3f2c249ef9c547705c639b642,
title = "Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients: A Cohort Study",
abstract = "Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear.Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIV-infected patients.Design: Cohort study.Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available.Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring.Results: A total of 52 479 treatment-naive patients (1339 [2.6{\%}] with chronic HBV infection and 7506 [14.3{\%}] with HCV infection) were included, of whom 40 219 (77{\%}) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatment-naive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95{\%} CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients.Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group.Conclusion: In HIV-infected patients receiving ART, chronic co-infection with HBV and HCV is associated with an increased risk for NHL.Primary Funding Source: European Union Seventh Framework Programme.",
keywords = "Journal Article",
author = "Qing Wang and Luca, {Andrea De} and Colette Smith and Robert Zangerle and Helen Sambatakou and Fabrice Bonnet and Colette Smit and Philipp Schommers and Alicia Thornton and Juan Berenguer and Lars Peters and Vincenzo Spagnuolo and Adriana Ammassari and Andrea Antinori and Eugenia Quiros-Roldan and Cristina Mussini and Miro, {Jose M.} and Deborah Konopnicki and Jan Fehr and Campbell, {Maria A} and Monique Termote and Bucher, {Heiner C.} and {Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord}",
year = "2016",
month = "10",
day = "18",
doi = "10.7326/M16-0240",
language = "English",
pages = "1--9",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",

}

TY - JOUR

T1 - Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients

T2 - A Cohort Study

AU - Wang, Qing

AU - Luca, Andrea De

AU - Smith, Colette

AU - Zangerle, Robert

AU - Sambatakou, Helen

AU - Bonnet, Fabrice

AU - Smit, Colette

AU - Schommers, Philipp

AU - Thornton, Alicia

AU - Berenguer, Juan

AU - Peters, Lars

AU - Spagnuolo, Vincenzo

AU - Ammassari, Adriana

AU - Antinori, Andrea

AU - Quiros-Roldan, Eugenia

AU - Mussini, Cristina

AU - Miro, Jose M.

AU - Konopnicki, Deborah

AU - Fehr, Jan

AU - Campbell, Maria A

AU - Termote, Monique

AU - Bucher, Heiner C.

AU - Hepatitis Coinfection and Non Hodgkin Lymphoma project team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord

PY - 2016/10/18

Y1 - 2016/10/18

N2 - Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear.Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIV-infected patients.Design: Cohort study.Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available.Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring.Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatment-naive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients.Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group.Conclusion: In HIV-infected patients receiving ART, chronic co-infection with HBV and HCV is associated with an increased risk for NHL.Primary Funding Source: European Union Seventh Framework Programme.

AB - Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defining condition in the era of antiretroviral therapy (ART). Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-infected patients is unclear.Objective: To investigate whether chronic HBV and HCV infection are associated with increased incidence of NHL in HIV-infected patients.Design: Cohort study.Setting: 18 of 33 cohorts from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE).Patients: HIV-infected patients with information on HBV surface antigen measurements and detectable HCV RNA, or a positive HCV antibody test result if HCV RNA measurements were not available.Measurements: Time-dependent Cox models to assess risk for NHL in treatment-naive patients and those initiating ART, with inverse probability weighting to control for informative censoring.Results: A total of 52 479 treatment-naive patients (1339 [2.6%] with chronic HBV infection and 7506 [14.3%] with HCV infection) were included, of whom 40 219 (77%) later started ART. The median follow-up was 13 months for treatment-naive patients and 50 months for those receiving ART. A total of 252 treatment-naive patients and 310 treated patients developed NHL, with incidence rates of 219 and 168 cases per 100 000 person-years, respectively. The hazard ratios for NHL with HBV and HCV infection were 1.33 (95% CI, 0.69 to 2.56) and 0.67 (CI, 0.40 to 1.12), respectively, in treatment-naive patients and 1.74 (CI, 1.08 to 2.82) and 1.73 (CI, 1.21 to 2.46), respectively, in treated patients.Limitation: Many treatment-naive patients later initiated ART, which limited the study of the associations of chronic HBV and HCV infection with NHL in this patient group.Conclusion: In HIV-infected patients receiving ART, chronic co-infection with HBV and HCV is associated with an increased risk for NHL.Primary Funding Source: European Union Seventh Framework Programme.

KW - Journal Article

U2 - 10.7326/M16-0240

DO - 10.7326/M16-0240

M3 - Article

C2 - 27750294

SP - 1

EP - 9

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

ER -